Glabellar LinesPhase 3NCT07870694
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Phase 3 study testing HU-045 and Xeomin® in people with Glabellar Lines, run by Huons Biopharma at 1 site in South Korea.
Trial summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines Read more about this study
- Who is it for?
- Ages 19 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Glabellar Lines
- What is being tested?
- HU-045 and Xeomin®
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 390 participants
- Where
- 1 siteSouth Korea
- Study dates
- 3 Sep 2026to Aug 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 19 to 65 years, inclusive, as of the date of written informed consent.
- Subjects who have a glabellar line severity score of 2 (moderate) or greater, as assessed by the investigator, when maximizing frown (frowning) at the screening and randomization visits.
- Subjects who are able to comply with the visit schedule according to the clinical trial procedures.
- Subjects who signed voluntarily in informed consent form and fully understood about this clinical trial.
Who cannot join
- Subjects with a known history of allergy or hypersensitivity to the investigational product or any of its components (or ingredients).
- Subjects with a systemic neuromuscular junction disorder that may affect neuromuscular function. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
- Subjects with an infection or skin disease at the treatment injection sites.
- Subjects with structural or physical facial features (or conditions) that may hinder or prevent improvement (facial nerve palsy or eyebrow/eyelid ptosis, marked facial asymmetry etc.)
- Subjects who have received drugs with systemic muscle relaxant action within 4 weeks of screening
- Subjects who have received botulinum toxin products within 24 weeks prior to screening, or who are expected to receive botulinum toxin treatment during the study.
Show all 22Show fewer
- Subjects who have received an investigational product or medical device in another clinical trial within 4 weeks prior to screening, or who are planning to participate in another clinical trial (excluding non-interventional observational studies).
- Subjects with a history of, or planned, surgery or procedures in the glabellar or forehead region that may affect the efficacy evaluation during the following period
- Collagen dermal fillers within 16 weeks prior to screening
- Permanent soft tissue augmentation, face Lifting, implant, or fat grafting within 24 weeks prior to screening
- Hyaluronic acid dermal fillers, dermal resurfacing, chemical or mechanical peeling, skin peeling, or dermal photorejuvenation within 52 weeks prior to screening
- Dermal fillers other than hyaluronic acid or collagen, or nonpermanent soft tissue fillers within 104 weeks prior to screening
- Subjects who are planning to undergo facial aesthetic procedures or surgeries (such as dermal fillers, dermal photorejuvenation, chemical or mechanical peeling, facial plastic surgery, etc.) during the study
- Subjects who have received retinoid products (such as isotretinoin, alitretinoin, etc.) during the following period
- Oral or other systemic formulations within 24 weeks prior to screening
- Topical formulations applied to the face within 12 weeks prior to screening
- Pregnant and lactating women
- Subjects who are planning to become pregnant during the study, or who do not agree to use medically acceptable methods of contraception.
- Subjects with any comorbid conditions or diseases that, in the opinion of the investigator, would interfere with study participation (such as malignant tumors or immunodeficiency)
- Subjects who have received anticoagulants, antiplatelets, or systemic non-steroidal anti-inflammatory drugs (NSAIDs) within 1 week prior to administration of the investigational product (low-dose aspirin of 325 mg/day or less administered for antithrombotic purposes is permitted).
- Subjects who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out
- Subjects who are not eligible for this study based on investigator's judgement.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Chung-Ang University Hospital
Seoul
About this study
Official title: A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Conditions
- Glabellar Lines
- Being tested
- HU-045, Xeomin®
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HU-045Drug
HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA
Xeomin®Drug
Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA
| Study group | Role | What they receive |
|---|---|---|
| HU-045 | Experimental | HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each. HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered. Receives: Drug: HU-045 |
| Xeomin® | Active comparator | Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each. Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered. Receives: Drug: Xeomin® |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator
Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or3=severe.
Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
Measured: Week4
Secondary outcomes (6)
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator
Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
Measured: Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Rest Are Improved as Assessed by the Investigator
Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
Measured: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved Based on Independent Evaluators' Photographic Assessment
Independent evaluators will assess participant's glabellar lines using photographs taken at rest with Facial Wrinkle Scale (FWS); 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
Measured: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Rest Are Improved Based on Independent Evaluators' Photographic Assessment
Independent evaluators will assess participant's glabellar lines using photographs taken at rest with Facial Wrinkle Scale (FWS); 0=none, 1=mild, 2=moderate or 3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
Measured: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines are Improved as Assessed by Participants
Participants will evaluate the improvement of their glabellar lines compared to baseline using the Subject Global Assessment (SGA) scale; -4 = very markedly worse to +4 = completely improved. Only the participants who achieve a score of +2 or higher will be defined as having improved glabellar lines.
Measured: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Satisfied with Treatment
Participants will evaluate their overall satisfaction with the treatment using the Participant Satisfaction (PS) scale; 1 = very dissatisfied to 7 = very satisfied. Only the participants who achieve a satisfaction score of 6 or higher will be defined as satisfied with the treatment.
Measured: Week 4, Week 8, Week 12, and Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study start3 Sep 2026
- Primary completionMay 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glabellar LinesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 390 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Huons Biopharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07870694
- Sponsor's protocol ID
- HU-045_P3_GL
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines
- ClinicalTrials.gov ID
- NCT07870694
- Acronym / sponsor ID
- HU-045_P3_GL
- Conditions
- Glabellar Lines
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 390 participants (estimated)
- Lead sponsor
- Huons BiopharmaIndustry (pharma, biotech, devices)
- Study start
- 3 Sep 2026 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HU-045 | Experimental | Drug: HU-045HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each. HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered. |
| Xeomin® | Active comparator | Drug: Xeomin®Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each. Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered. |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults aged 19 to 65 years, inclusive, as of the date of written informed consent.
- Subjects who have a glabellar line severity score of 2 (moderate) or greater, as assessed by the investigator, when maximizing frown (frowning) at the screening and randomization visits.
- Subjects who are able to comply with the visit schedule according to the clinical trial procedures.
- Subjects who signed voluntarily in informed consent form and fully understood about this clinical trial.
Key exclusion criteria (22 listed)
- Subjects with a known history of allergy or hypersensitivity to the investigational product or any of its components (or ingredients).
- Subjects with a systemic neuromuscular junction disorder that may affect neuromuscular function. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
- Subjects with an infection or skin disease at the treatment injection sites.
- Subjects with structural or physical facial features (or conditions) that may hinder or prevent improvement (facial nerve palsy or eyebrow/eyelid ptosis, marked facial asymmetry etc.)
- Subjects who have received drugs with systemic muscle relaxant action within 4 weeks of screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HU-045HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA | Drug | HU-045 |
| Xeomin®Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA | Drug | Xeomin® |
Primary outcome
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator
Time frame: Week4
Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or3=severe. Only the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved.
6 secondary outcomes
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator
Time frame: Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Rest Are Improved as Assessed by the Investigator
Time frame: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved Based on Independent Evaluators' Photographic Assessment
Time frame: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines at Rest Are Improved Based on Independent Evaluators' Photographic Assessment
Time frame: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Whose Glabellar Lines are Improved as Assessed by Participants
Time frame: Week 4, Week 8, Week 12, and Week 16
Percentage of Participants Satisfied with Treatment
Time frame: Week 4, Week 8, Week 12, and Week 16
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Glabellar Lines
RecruitingPhase 2
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
Upper Facial Lines, Glabellar Lines
Active, not recruitingPhase 1
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Glabellar Lines
Active, not recruitingPhase 3
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Moderate to Severe Glabellar Lines
RecruitingPhase 3
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
RecruitingPhase 3
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Moderate to Severe Glabellar Lines
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing HU-045 and Xeomin® in people with Glabellar Lines, run by Huons Biopharma at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Saeroarum Han (82-70-7492-6032, saeroarum@huonsbiopharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Whose Glabellar Lines at Maximal Frown Are Improved as Assessed by the Investigator (time frame: Week4). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.